Summary of Biomarker Analysis
Method of Measurement
Biomarker Measured
Biomarker Categories
Summary completed October 2019
Biomarkers for Alzheimer’s Disease
BiomarkerBACE1 |
Biomarker MeasuredBlood/Plasma |
Method of MeasurementAmyloid |
UseDiagnostic, Susceptibility/risk |
Stage of DevelopmentClinical trials |
BiomarkerNeuronal pentraxin 2 (NPTX2) |
Biomarker MeasuredCSF |
Method of MeasurementInflammation |
UseDiagnostic |
Stage of DevelopmentClinical trials |
BiomarkerB-vitamin deficiencies in blood and urine (BVB) |
Biomarker MeasuredBlood/Plasma, Other bodily fluids |
Method of MeasurementGenetic variation/DNA |
UseDiagnostic, Prognostic |
Stage of DevelopmentClinical trials |
BiomarkerAPP 669–711/Aβ 1–42 |
Biomarker MeasuredBlood/Plasma |
Method of MeasurementAmyloid |
UsePrognostic |
Stage of DevelopmentPreclinical |
BiomarkerNFL (neurofilament light chain) (CSF) |
Biomarker MeasuredCSF |
Method of MeasurementNeuronal damage |
UseDiagnostic |
Stage of DevelopmentClinical trials |
BiomarkerAPOE4 |
Biomarker MeasuredBlood/Plasma, Other bodily fluids |
Method of MeasurementGenetic variation/DNA |
UseSusceptibility/risk |
Stage of DevelopmentIn use (FDA approved) |
BiomarkerNSE (neuron specific enolase) |
Biomarker MeasuredCSF |
Method of MeasurementNeuronal damage |
UseSusceptibility/risk, Predictive |
Stage of DevelopmentClinical trials |
BiomarkerAmyvid (florbetapir F18 injection) |
Biomarker MeasuredImaging |
Method of MeasurementAmyloid |
UseDiagnostic |
Stage of DevelopmentIn use (FDA approved) |
BiomarkerAlbumin ratio |
Biomarker MeasuredBlood/Plasma, CSF |
Method of MeasurementAmyloid |
UseDiagnostic |
Stage of DevelopmentClinical trials |
BiomarkerADDIA blood biomarkers |
Biomarker MeasuredBlood/Plasma |
Method of MeasurementOther |
UseDiagnostic |
Stage of DevelopmentClinical trials |
BiomarkerAβ42/ Aβ40 (Plasma) |
Biomarker MeasuredBlood/Plasma |
Method of MeasurementAmyloid |
UsePharmacodynamic/response, Susceptibility/risk, Safety |
Stage of DevelopmentClinical trials |
BiomarkerObesity and Epigenetic markers (Oba) |
Biomarker MeasuredGene |
Method of MeasurementGenetic variation/DNA |
UseSusceptibility/risk, Predictive |
Stage of DevelopmentClinical trials |
BiomarkerAβ1-42/ Aβ1-40 (CSF) |
Biomarker MeasuredCSF |
Method of MeasurementAmyloid |
UseDiagnostic, Prognostic |
Stage of DevelopmentClinical trials |
BiomarkerAβ42 (salivary) |
Biomarker MeasuredOther bodily fluids |
Method of MeasurementAmyloid |
UseDiagnostic, Prognostic |
Stage of DevelopmentClinical trials |
BiomarkerOptical coherence tomography angiography (OCTA) |
Biomarker MeasuredOptical |
Method of MeasurementVasculature |
UseDiagnostic |
Stage of DevelopmentClinical trials |
BiomarkerAβ42 (blood) |
Biomarker MeasuredBlood/Plasma |
Method of MeasurementAmyloid |
UseDiagnostic |
Stage of DevelopmentClinical trials |
BiomarkerOrientation |
Biomarker MeasuredImaging |
Method of MeasurementUnknown |
UsePharmacodynamic/response |
Stage of DevelopmentClinical trials |
BiomarkerAβ42 (CSF) |
Biomarker MeasuredCSF |
Method of MeasurementAmyloid |
UseDiagnostic, Prognostic, Susceptibility/risk |
Stage of DevelopmentClinical trials |
BiomarkerOxidative Stress and Nutrition Biomarkers (GERIOX) |
Biomarker MeasuredBlood/Plasma |
Method of MeasurementOxidative stress |
UseSusceptibility/risk |
Stage of DevelopmentClinical trials |
BiomarkerPhosphorylated tau231 (P-tau231) |
Biomarker MeasuredCSF |
Method of MeasurementTau |
UseDiagnostic |
Stage of DevelopmentClinical trials |
Questions? Additional biomarkers to share? Contact Us